In response to the call of the Improvement Plan for Healthy Children Action (2021-2025), the "Zhongnanshan Medical Foundation of Guangdong Province - Innovita Special Health Fund" was established jointly by Innovita Biological Technology Co., Ltd. and Zhongnanshan Medical Foundation of Guangdong Province based on their advantages and development potentials in respective business fields, so as to jointly promote improving the capability and level of service in children's health, and strive to provide continuous and comprehensive services for children's health. The Fund was established to actively promote the diagnosis, treatment and screening of common children's diseases, improve the therapeutic effect, and lower the burden of child patients, family members, medical institutions and society. Meanwhile, it is also aimed at facilitating the clinical transformation of relevant latest scientific research achievements in the screening of common children's diseases. The project was publicized by Zhongnanshan Medical Foundation of Guangdong Province through its official website on December 15. 

As shown by the WHO data, 920,000 children ＜5 years old died of pneumonia in 2016, 98% of whom came from the developing countries. Pneumonia is also one of the main causes of death in children ＜5 years old in China, of which the vast majority is community-acquired pneumonia (CAP). The airway occlusion, left over by the severe refractory mycoplasma pneumonia and adenovirus pneumonia among community-acquired pneumonia, is an important cause for the children undergoing chronic airway diseases, thus affecting their quality of life. In addition, the incidence rate of allergic diseases in children has risen year by year, which has been widely concerned by the public and medical workers. 

As suggested by the Chinese epidemiological survey of allergic diseases in urban infants and young children, 40.9% of the patients of infants aged 0-24 months reported that their children underwent or are showing symptoms of allergic disease. The total prevalence rate of allergic diseases in infants aged 0-24 months is 12.3%. Allergic diseases, as a kind of pediatric common chronic diseases, have severely affected the life and health of child patients. Meanwhile, during the process of clinical practice, there still are problems, including unclear understanding, untimely treatment, numerous missed diagnoses and misdiagnoses, and non-standard treatment, which are in urgent need of being solved jointly by all sectors of society. Respiratory tract infection, allergy and relevant diseases are the first category of diseases affecting the life, health and quality of life of the children, and have a long-term impact on the prognosis, body and late growth of children. On account of the particularity of children, such diseases also bring heavy social burden to the parents of child patients and the whole society. 

The policy documents including the Opinion of the State Council on Implementing Healthy China Action, the "Healthy China 2030" Planning Outline, the "14^th Five-Year Plan" Health Planning, and the Improvement Plan for Healthy Children Action (2021-2025) have successively introduced, indicating the working direction for the standardized diagnosis and treatment of the children-related diseases in China. In this context, Innovita Biological Technology Co., Ltd. and Zhongnanshan Medical Foundation of Guangdong Province jointly established "Zhongnanshan Medical Foundation of Guangdong Province - Innovita Special Health Fund". Among others, domestic famous pediatric respiratory specialist Shen Kunling, as well as Prof. Sun Baoqing and Prof. Zheng Yuejie, were employed to respectively serve as the Vice Chairman and the members of this Special Fund.